BELLUS Health Inc. (BLU): Price and Financial Metrics


BELLUS Health Inc. (BLU): $3.63

-0.02 (-0.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BLU to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

BLU POWR Grades


  • BLU scores best on the Growth dimension, with a Growth rank ahead of 40.58% of US stocks.
  • BLU's strongest trending metric is Momentum; it's been moving down over the last 200 days.
  • BLU ranks lowest in Quality; there it ranks in the 5th percentile.

BLU Stock Summary

  • For BLU, its debt to operating expenses ratio is greater than that reported by only 5.26% of US equities we're observing.
  • BLU's price/sales ratio is 24,017.75; that's higher than the P/S ratio of 99.89% of US stocks.
  • With a year-over-year growth in debt of 282.91%, BELLUS Health Inc's debt growth rate surpasses 95.68% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to BELLUS Health Inc, a group of peers worth examining would be NYMX, SPCE, INMB, CYAD, and TGTX.
  • BLU's SEC filings can be seen here. And to visit BELLUS Health Inc's official web site, go to www.bellushealth.com.

BLU Price Target

For more insight on analysts targets of BLU, see our BLU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.32 Average Broker Recommendation 1.57 (Moderate Buy)

BLU Stock Price Chart Interactive Chart >

Price chart for BLU

BLU Price/Volume Stats

Current price $3.63 52-week high $12.03
Prev. close $3.65 52-week low $2.01
Day low $3.49 Volume 194,470
Day high $3.70 Avg. volume 1,186,453
50-day MA $4.10 Dividend yield N/A
200-day MA $3.19 Market Cap 284.36M

BELLUS Health Inc. (BLU) Company Bio


BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.


BLU Latest News Stream


Event/Time News Detail
Loading, please wait...

BLU Latest Social Stream


Loading social stream, please wait...

View Full BLU Social Stream

Latest BLU News From Around the Web

Below are the latest news stories about BELLUS Health Inc that investors may wish to consider to help them evaluate BLU as an investment opportunity.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BELLUS Health Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2021 - BLU

New York, New York--(Newsfile Corp. - May 10, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of BELLUS Health Inc. ("BELLUS Health") (NASDAQ: BLU) between September 5, 2019 and July 5, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To ...

Yahoo | May 10, 2021

BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the first quarter ending March 31, 2021.

Yahoo | May 10, 2021

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BELLUS Health Inc. Investors with Losses over $100K to Secure Counsel Before Important May 17 Deadline in Securities Class Action – BLU

NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and July 5, 2020, inclusive (the “Class Period”), of the important May 17, 2021 lead plaintiff deadline. SO WHAT: If you purchased BELLUS securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the BELLUS class action, go to http://www.rosenlegal.com/cases-register-2058.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If y...

Yahoo | May 10, 2021

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLU, SOS and NEPT

NEW YORK, NY / ACCESSWIRE / May 10, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

Yahoo | May 10, 2021

DEADLINE ALERT for NEPT, BLU, RIDE, and CYDY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, May 10, 2021 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] Neptune Wellness Solutions Inc. (NASDAQ: NEPT)Class Period: July 24, 2019 – February 16, 2021Lead Plaintiff Deadline: May 17, 2021 The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose mater...

Yahoo | May 10, 2021

Read More 'BLU' Stories Here

BLU Price Returns

1-mo -17.12%
3-mo -4.72%
6-mo 48.16%
1-year -64.59%
3-year N/A
5-year -41.68%
YTD 18.63%
2020 -59.74%
2019 175.96%
2018 155.26%
2017 N/A
2016 0.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9051 seconds.